Victory Pharma
Leveraging science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in the areas of infectious diseases and pain.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $118m | Acquisition | |
$7.6m | Grant | ||
| Total Funding | $7.6m | ||
| JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 13 % | 27 % | 2 % | 1 % | 13 % | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 53 % | 43 % | 57 % | 51 % | 53 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 38 % | 34 % | 43 % | 37 % | 39 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 18 % | 22 % | 24 % | 24 % | 25 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Victory Pharma, Inc. was a specialty pharmaceutical company headquartered in San Diego, California, that concentrated on the development and commercialization of products for treating pain and associated conditions. Founded in 2003, the company directed its marketing efforts towards pain management specialists, rheumatologists, orthopedic surgeons, and select primary care physicians.
The company's business model centered on acquiring, developing, and marketing pharmaceutical products. A significant milestone was the 2010 acquisition of assets from MiddleBrook Pharmaceuticals, which added anti-infective products like MOXATAG® and KEFLEX® to its portfolio, complementing its primary pain products. This move was strategic, designed to balance its portfolio since the peak use of its lead pain product, NAPRELAN®, was in spring and summer, while the newly acquired anti-infectives saw higher demand during the flu season.
In August 2011, Shionogi, Inc., the U.S.-based subsidiary of the Japanese pharmaceutical firm Shionogi & Co., Ltd., acquired all of Victory Pharma's marketed products. This transaction, valued at $118 million with up to $9 million in potential milestone payments, included seven pain medications and two infectious disease treatments. The acquisition allowed Shionogi to immediately establish a market presence in these therapeutic areas in the United States, utilizing its existing sales force to market the newly acquired FDA-approved products. Victory's lead product was NAPRELAN, a controlled-release formulation of naproxen sodium, an NSAID for pain management. Following the acquisition, in December 2012, Victory Pharma agreed to a settlement of over $11.4 million to resolve federal civil and criminal liability related to allegations of using kickbacks to promote its drugs.
Keywords: Victory Pharma, Shionogi, pharmaceutical acquisition, pain management drugs, specialty pharmaceuticals, Naprelan, Xodol, Fexmid, Dolgic, MiddleBrook Pharmaceuticals, MOXATAG, KEFLEX, anti-infective products, NSAID, controlled-release formulation, drug commercialization, rheumatology, orthopedic surgery, primary care physicians, pharmaceutical marketing, asset acquisition
